Practicing What We Preach!

Restricted access

Robert J. Morgan Jr, MD, is Professor of Medical Oncology, Department of Medical Oncology and Therapeutics Research, at City of Hope Comprehensive Cancer Center, where he also is Co-director Gynecological Cancers Program; Co-director, Gynecological Oncology/Peritoneal Malignancy Program; Director, Continuing Medical Education; and Associate Director for Medical Education, Medical Oncology & Therapeutics Research. He is also Assistant Clinical Professor of Medicine at UCLA Medical School.

Dr. Morgan earned his medical degree at the University of Illinois College of Medicine. He completed a fellowship in medical oncology and therapeutics research at City of Hope National Medical Center, as well as a research fellowship in hematology, fellowship in hematology, and residency in internal medicine at Mayo Graduate School of Medicine. Dr. Morgan is board certified in internal medicine, hematology, medical oncology, and palliative care medicine.

Dr. Morgan is a member of numerous NCCN committees, including serving as Chair of the NCCN Ovarian Cancer Panel. His primary research interests are in new drug development, primarily in gynecologic cancers, and regional approaches to chemotherapy administration.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1.

    Siegel R, Ma J, Zou Z. Cancer statistics, 2014. CA Cancer J Clin 2014;64:929.

  • 2.

    Morgan RJ Jr, Copeland L, Gershenson D. NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996;10(11 Suppl):293310.

    • Search Google Scholar
    • Export Citation
  • 3.

    Alberts DS, Liu PY, Hannigan EV. Phase III study of intraperitoneal cisplatin (CDDP)/intravenous cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study (INT 0051)[abstract]. Proc Am Soc Clin Oncol 1995;14:Abstract 273.

    • Search Google Scholar
    • Export Citation
  • 4.

    Markman M, Bundy BN, Alberts DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma. J Clin Oncol 2001;19:10011007.

    • Search Google Scholar
    • Export Citation
  • 5.

    Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 6.

    Morgan RJ Jr, Armstrong DK, Alvarez RD. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3. 2014. Available at NCCN.org. Accessed January 21, 2015.

    • Search Google Scholar
    • Export Citation
  • 7.

    Wenzel LB, Huang HQ, Armstrong DK. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer. J Clin Oncol 2007;25:437443.

    • Search Google Scholar
    • Export Citation
  • 8.

    Wright AA, Cronin A, Milne D. Effect of intraperitoneal chemotherapy on survival for ovarian cancer in clinical practice and frequency of use [abstract]. J Clin Oncol 2014;32:Abstract 5576.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 20 13 0
PDF Downloads 10 9 1
EPUB Downloads 0 0 0